BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30701033)

  • 1. Green tea extract for prevention of prostate cancer progression in patients on active surveillance.
    Kumar NB; Dickinson SI; Schell MJ; Manley BJ; Poch MA; Pow-Sang J
    Oncotarget; 2018 Dec; 9(102):37798-37806. PubMed ID: 30701033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.
    Kumar NB; Hogue S; Pow-Sang J; Poch M; Manley BJ; Li R; Dhillon J; Yu A; Byrd DA
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial.
    Micali S; Territo A; Pirola GM; Ferrari N; Sighinolfi MC; Martorana E; Navarra M; Bianchi G
    Arch Ital Urol Androl; 2017 Oct; 89(3):197-202. PubMed ID: 28969404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
    Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
    Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.
    Connors SK; Chornokur G; Kumar NB
    Nutr Cancer; 2012; 64(1):4-22. PubMed ID: 22098273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
    Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
    Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green tea catechins for chemoprevention of prostate cancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis.
    Perletti G; Magri V; Vral A; Stamatiou K; Trinchieri A
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
    Bettuzzi S; Brausi M; Rizzi F; Castagnetti G; Peracchia G; Corti A
    Cancer Res; 2006 Jan; 66(2):1234-40. PubMed ID: 16424063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures.
    Kumar N; Crocker T; Smith T; Connors S; Pow-Sang J; Spiess PE; Egan K; Quinn G; Schell M; Sebti S; Kazi A; Chuang T; Salup R; Helal M; Zagaja G; Trabulsi E; McLarty J; Fazili T; Williams CR; Schreiber F; Anderson K
    J Clin Trials; 2012 Jan; 2(1):. PubMed ID: 24533253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention in African American Men With Prostate Cancer.
    Kumar NB; Pow-Sang JM; Spiess PE; Park JY; Chornokur G; Leone AR; Phelan CM
    Cancer Control; 2016 Oct; 23(4):415-423. PubMed ID: 27842331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
    Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
    J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
    Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
    Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.
    Kumar NB; Patel R; Pow-Sang J; Spiess PE; Salup R; Williams CR; Schell MJ
    Oncotarget; 2017 Nov; 8(58):99093-99103. PubMed ID: 29228755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Green Tea Consumption on Prostate Cancer Risk and Progression: A Systematic Review.
    Jacob SA; Khan TM; Lee LH
    Nutr Cancer; 2017 Apr; 69(3):353-364. PubMed ID: 28287319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer chemoprevention by green tea.
    Gupta S; Ahmad N; Mukhtar H
    Semin Urol Oncol; 1999 May; 17(2):70-6. PubMed ID: 10332919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green tea and the risk of prostate cancer: A systematic review and meta-analysis.
    Guo Y; Zhi F; Chen P; Zhao K; Xiang H; Mao Q; Wang X; Zhang X
    Medicine (Baltimore); 2017 Mar; 96(13):e6426. PubMed ID: 28353571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.
    Henning SM; Wang P; Said JW; Huang M; Grogan T; Elashoff D; Carpenter CL; Heber D; Aronson WJ
    Prostate; 2015 Apr; 75(5):550-9. PubMed ID: 25545744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer.
    Giudice A; Montella M; Boccellino M; Crispo A; D'Arena G; Bimonte S; Facchini G; Ciliberto G; Botti G; Quagliuolo L; Caraglia M; Capunzo M
    Curr Mol Med; 2017; 17(6):405-420. PubMed ID: 29256350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.